[New] After the announced transition period, the Saskatchewan Drug Plan will no longer cover the reference biologic medication.
Government of Saskatchewan
[New] Patients who are currently using an affected reference biologic medication will need to transition to a biosimilar version by the end of the announced transition period to maintain Saskatchewan Drug Plan coverage of their treatment.
Government of Saskatchewan
[New] Pharmaceutical companies such as Amgen, Eli Lilly, and Pfizer are expected to grow their leadership by investing in new injectables, patient support programs, and education for specialists.
Precedence Research
[New] Starting in 2028, prescription drug plan sponsors must allow any pharmacy meeting standard contract terms and conditions to participate in their networks.
Buchanan Ingersoll & Rooney PC
[New] Pharmaceutical supply chain integrity is critical for patient safety, with counterfeit medications representing a significant global health threat.
Mobile App Development Company
[New] By Drug Type, the hormone replacement therapy (HRT) segment is expected to expand at the fastest CAGR of 8.1% between 2024 and 2034 By Distribution Channel, the retail pharmacy segment captured more than 39% of revenue share in 2023.
Precedence Research
[New] The 2026 regulatory environment in the EU is tightening, with new pharmaceutical legislation aimed at reducing the period of data exclusivity for new drugs, which could impact long-term profitability. / UK
The Chronicle-Journal
[New] Reductions in NIH funding and regulatory delays could result in dozens fewer new drug approvals and disrupt tens of thousands of patients enrolled in clinical trials.
AJMC
[New] Health officials are warning that drug poisonings are on the rise across B.C., with a new single-day record for most drug poisonings attended by paramedics being set last week.
CBC
[New] The Union Budget 2026-27 has announced Biopharma SHAKTI, a Rs10,000 crore initiative aimed at strengthening India's biologics and biosimilars ecosystem, signalling a strategic shift from generic drug manufacturing to high-value, innovation-driven biopharmaceuticals.
KPs 21st Century IAS Academy
[New] The US Food and Drug Administration has approved Ozempic tablets, an oral form of semaglutide, with availability expected in the United States in the second quarter of 2026.
Rejoy Health
[New] Biogen is betting that growth from newer drugs - including Alzheimer's treatment Leqembi and rare-disease drugs Skyclarys and Spinraza - will offset its declining multiple sclerosis medicines as competition from generics erode sales.
The Edge Malaysia
[New] By 2026, digital transformation in the pharmaceutical industry will no longer be about isolated technologies, but integration.
Voka
[New] AI-powered pharmacogenomics could reduce adverse drug reactions by up to 30% and improve therapeutic efficacy by 25% across major drug classes.
BUSINESS 2.0 NEWS
[New] With a projected 32.6% CAGR through 2029 and genome sequencing costs plummeting toward $200, AI-powered genomics is reshaping personalized medicine, drug discovery, and clinical diagnostics across the global healthcare ecosystem.
BUSINESS 2.0 NEWS
[New] Pfizer's oncology drug Ibrance will likely see generic competition in 2027, with cardiovascular offerings Eliquis and Vyndaqel next up in 2028.
Nasdaq
[New] Drug-resistant infections could cause 10 million deaths annually by 2050, surpassing deaths from cancer. / USA
Market.us Media
Last updated: 17 February 2026
Hi,
Would you like a quick online demo of our service from an experienced member of our team?
